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Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by
dysregulated autoantibody production and complement activation leading to multi-organ
damage. The disease is associated with increased intestinal permeability. In this study,
we tested the hypothesis that SLE subjects have increased systemic exposure to
bacteria. Since bacteria induce the expression of antimicrobial response factors (ARFs),
we measured the levels of a series of clinically relevant ARFs in the plasma of SLE
subjects. We found that levels of sCD14, lysozyme, and CXCL16 were significantly
elevated in SLE subjects. A strong positive correlation was also observed between
sCD14 and SELENA-SLEDAI score. Interestingly, the ratio of EndoCAb IgM:total IgM
was significantly decreased in SLE and this ratio was negatively correlated with sCD14
levels. Although, there were no significant differences in the levels of lipopolysaccharide
binding protein (LBP) and fatty acid binding protein 2 (FABP2), we observed significant
positive correlations between lysozyme levels and sCD14, LBP, and FABP2. Moreover,
galectin-3 levels also positively correlate with lysozyme, sCD14, and LBP. Since our SLE
cohort comprised 43.33%males, we were able to identify gender-specific changes in the
levels of ARFs. Overall, these changes in the levels and relationships between ARFs link
microbial exposure and SLE. Approaches to reduce microbial exposure or to improve
barrier function may provide therapeutic strategies for SLE patients.
Keywords: antimicrobial proteins, SLE, EndoCAbs, sCD14, lysozyme, lipopolysaccharide binding protein, fatty
acid binding protein, CXCL16
INTRODUCTION
Systemic lupus erythematosus (SLE) is a heterogeneous chronic autoimmune disease, primarily
affecting women with a gender bias of 9:1 (1). The initiating stimulus of SLE is unknown. SLE is
characterized by dysregulated autoantibody production and complement activation. Target tissues
include the central nervous system (CNS), kidneys, blood, skin, and joints (2). Diagnosis of SLE is
based on clinical manifestations, mainly in the skin and musculoskeletal tissues. A large proportion
of subjects present with either hyperkeratosis, maculopapular exanthema, synovitis, myalgia, or
arthralgia (3). Due to its heterogeneous nature and diverse clinical manifestations, it is difficult to
accurately diagnose SLE (4). Genetic susceptibility as well as environmental and epigenetic factors
contribute to the pathogenesis of this disease (1, 5, 6).
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Recent reports suggest that intestinal barrier defects
and exposure to microbial products play an important
role in the pathology of SLE (7–9). Furthermore, exposure
to products from Gram-negative bacteria such as LPS
aggravate SLE (10). It has been postulated that products
from both Gram-negative and Gram-positive bacteria
act as initiating or accelerating factors for this disease
(11–13). A significant alteration in the gut microbiome
was also observed in human SLE (7, 14, 15). Alterations
in the intestinal microbiome composition and leakage
into the body could promote a toxic inflammatory
microenvironment, leading to loss of self-tolerance and
autoimmunity (14–16).
Exposure to microbes and their products elicits the
production of antimicrobial response factors (ARFs). ARFs
comprise the first line of defense against infection. ARFs
include proteases, cytokines, chemokines, and peptides (17).
ARFs directly kill bacteria and/or activate innate immunity
(18) by recruiting neutrophils and macrophages. This
facilitates rapid microbial clearance, and ultimately reduces
inflammation (19).
In the present study, we tested the hypothesis that SLE
subjects have increased exposure to bacteria. We asked
whether these subjects exhibited heightened circulating
levels of ARFs. To query this, we measured the levels of
a series of representative ARFs in plasma from female
and male SLE subjects. The tested factors include sCD14,
lipopolysaccharide-binding protein (LBP), EndoCAb IgG,
IgM, and IgA, lysozyme, galectin-3, CXCL16, and LL-37.
We also measured fatty acid binding protein-2 (FABP2)
levels, since this reflects intestinal damage (20). Our results
demonstrate a marked elevation of sCD14, lysozyme and
CXCL16 in SLE subjects. In addition, we observed a
reduction in the levels of EndoCAb IgM, suggesting acute
bacterial exposure. We discovered significant correlations
between lysozyme and sCD14 levels, and these factors also
correlated with LBP, galectin-3 and FABP2, suggesting a
common stimulus.
MATERIALS AND METHODS
Study Subjects
Ethical approval for this study was obtained from Benaroya
Research Institute’s Institutional Review Board (#07109-136) in
compliance with Declaration of Helsinki. Informed consents
were obtained from each participant prior to including them
in the study. Our study involved 30 SLE patients (13 males
and 17 females), all fulfilling the revised classification criteria
for SLE from the American College of Rheumatology (21)
and 30 age and gender matched healthy control subjects
(16 females and 14 males) with no personal or family
history of autoimmunity. Exclusion criteria included history
of recent infection and the use of steroids from the past
6 months. Out of 30 SLE subjects, 19 were treated with
immunosuppressive and/or immunomodulatory drugs, which
include mycophenolate mofetil, methotrexate, azathioprine,
and hydroxychloroquine.
Sample Collection
Venous blood was drawn from both SLE and control individuals
in BD Vacutainer R© K2 EDTA tubes (Franklin Lakes, NJ, USA).
The collected whole blood was centrifuged (for 20min at 3000
× g and 20◦C) and then the plasma layer was removed.
All the plasma samples were divided into multiple aliquots
and were flash frozen in dry ice and stored at −80◦C until
analysis. Patient data is provided in Table 1. Individual ARF
values, disease activity, drug use, and ANA titres are given in
Supplementary Tables 1–3.
Measurement of Analytes in the Plasma
EndoCAb IgG, EndoCAb IgM, and EndoCAb IgA were
measured using direct ELISA kits procured from Hycult
Biotech. LBP and LL-37 were measured using sandwich
ELISA kits procured from Hycult Biotech (Pennsylvania, USA).
sCD14 and FABP2 were measured using sandwich ELISA
kits from R&D systems (Minneapolis, USA). CXCL16 was
analyzed using a sandwich ELISA kit procured from Thermo
Scientific (Frederick, MD, USA). Galectin-3 was measured
using sandwich ELISA kit (Abcam, MA, USA). Total IgG,
IgA, and IgM were measured using sandwich ELISA kits
procured from Invitrogen (Carlsbad, CA, USA). The samples
were diluted in appropriate buffers, which contains HeteroBlock
(Omega Biologicals, Bozeman, MT, USA) to block non-
specific antibodies which may interfere with the assay. All the
analyses were performed blinded to clinical status with the
exception of galectin-3 and total immunoglobulins IgG, IgA,
and IgM.
Statistical Analysis
We transformed the data into logarithmic values for statistical
analysis and correlation studies. For testing statistical
significance, the unpaired t-test was used. For correlation
analysis, Pearson product-moment correlation coefficient
(Pearson’s r) analysis was performed. For all statistical tests,
P < 0.05 was considered to be statistically significant. All the
statistical tests were done with GraphPad Prism 7 (GraphPad
Software, Inc.).
TABLE 1 | Characteristics of SLE patients and healthy controls.
SLE Patients
(n = 30)
Healthy controls
(n = 30)
Mean age in years
(range)
45.90 ± 13.04
(30–71)
46.13 ± 13.00
(26–68)
Sex (n) Female 17 16
Male 13 14
Mean
SELENA-SLEDAI#
score (range)
4.90±5.98 (0–26) –
ANA* titer (range) 1:80 to >1:640 –
Values expressed as mean± standard deviation (SD) wherever it is applicable. #SELENA-
SLEDAI- Safety of Estrogens in Lupus Erythematosus National Assessment-systemic
lupus erythematosus disease activity index. *ANA-antinuclear antibodies.
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RESULTS
sCD14 Levels Are Increased in
SLE Patients
CD14 is a co-receptor for LPS and is expressed by monocytes
and macrophages (22). Upon stimulation with endotoxins, CD14
is shed from the cell surface leading to increased circulatory
levels of soluble CD14 (sCD14). Increased levels of sCD14
could reflect endotoxin exposure and/or monocyte/macrophage
activation (23). We found a significant increase in the levels
of sCD14 (P < 0.0001) in SLE patients compared to control
subjects (Figure 1A). We also compared sCD14 levels in male
and female SLE subjects. Both SLE males and females showed
significant elevations in sCD14 compared to controls (P= 0.0101
and P = 0.0004 for males and females, respectively). LBP binds
to LPS and transfers LPS to CD14, leading to the activation of
TLR4 (22, 24). We did not detect a significant difference in LBP
levels in SLE patients compared to healthy controls (P = 0.180).
However, SLE males showed a trend toward increased levels
(P= 0.062), whereas SLE females were not different than controls
(P = 0.765) (Figure 1B).
sCD14 Positively Correlates
With SELENA-SLEDAI
Safety of Estrogens in Lupus Erythematosus National
Assessment-Systemic Lupus Erythematosus Disease Activity
Index (SELENA-SLEDAI) is a modified version of the measure
of disease activity, which is used as a clinical index for
the severity of the disease (25, 26). SLEDAI levels reflect
alterations in mucocutaneous, musculoskeletal, neurological,
cardiopulmonary, renal, and hematological systems (27). Since
we found an elevation in sCD14 in SLE patients, we asked
whether sCD14 and SELENA-SLEDAI levels were correlated
in SLE patients. Interestingly, sCD14 levels were positively
correlated with SLEDAI score in both lupus male subjects (r =
0.774 and P = 0.014) and female subjects (r = 0.812 and P =
0.049) (Figure 1C).
EndoCAb IgM Levels and Proportions Are
Reduced in SLE Patients
EndoCAbs are antibodies directed against the endotoxin core of
LPS (28). They bind and neutralize circulating LPS. Alterations
in the levels of EndoCAbs occur upon exposure to LPS and serve
as a measure of bacterial exposure (20, 28, 29). Evaluation of
EndoCAbs revealed that there is no significant differences in
the levels of EndoCAb IgG and EndoCAb IgA between control
and SLE patients (Figures 2A,B). Interestingly, we observed a
significant decrease in EndoCAb IgM levels in SLE subjects (P =
0.002) compared to controls (Figure 2C). Gender comparisons
revealed that SLE females had reduced levels of EndoCAb IgM
(P = 0.008), whereas SLE males only showed a trend toward
significance (P = 0.08). We next measured the concentration of
total immunoglobulins (Igs) in the SLE and control cohorts. The
results revealed a significant increase in the levels of total IgG (P
= 0.0004) and total IgA (P = 0.013) in SLE patients compared to
healthy controls (Figures 2D,E), confirming earlier observations
(30, 31). SLE females showed an elevation of total IgA compared
to control females (P = 0.014), whereas SLE males didn’t show a
significant change compared to control males (P = 0.381). Both
SLE males (P = 0.0078) and SLE females (P = 0.027) showed a
significant elevation in the levels of total IgG compared to their
respective controls. We did not find a significant difference in
total IgM levels (P = 0.153 healthy controls vs. SLE patients; P
= 0.486 control males vs. SLE males; P = 0.160 control females
vs. SLE females) (Figure 2F).
In order to determine whether the proportion of EndoCAbs
were altered in SLE subjects; we determined the ratios of
EndoCAb IgA:total IgA, EndoCAb IgG:total IgG, and EndoCAb
IgM:total IgM between the groups. We did not find a significant
change in the ratios of EndoCAb IgG:total IgG (P = 0.567
healthy controls vs. SLE; P = 0.953 control male vs. SLE male;
P = 0.525 control female vs. SLE female). However, EndoCAb
IgA:total IgA levels showed a trend toward reduction in females
but not in males (P = 0.176 healthy controls vs. SLE; P =
0.521 control male vs. SLE male; P = 0.059 control female vs.
SLE female) between the groups (Figures 2G,H). Interestingly,
we observed a significantly reduced ratio of EndoCAb IgM:total
IgM in SLE subjects compared to healthy controls (P = 0.006)
(Figure 2I). SLE females showed reduced EndoCAb IgM:total
IgM ratios (P = 0.015), whereas in males the difference was not
significant (P = 0.140).
To determine whether these observations could be explained
by the effects of immunosuppressive and/or immunomodulatory
drugs, we compared the levels of total Igs, EndoCAbs, and
the ratios of EndoCAbs:total Igs between treated and untreated
SLE subjects. Total IgG (P = 0.557), IgA (P = 0.173), IgM
(P = 0.139), and EndoCAb IgG (P = 0.402) levels were the same
in SLE patients untreated and treated with immunosuppressive
and/or immunomodulatory drugs (Figures 3A–D). However,
EndoCAb IgA and EndoCAb IgM levels were found to be reduced
significantly in SLE patients treated with immunosuppressive
drugs compared to untreated SLE patients (P = 0.035 & P =
0.025, respectively) (Figures 3E,F). Importantly, the ratio of the
three EndoCAbs:total Igs was not affected by immunosuppressive
drugs in SLE subjects (Figures 3G–I).
Since, both EndoCAbs and sCD14 are responsive to LPS, we
asked whether the ratios of EndoCAbs:total Igs were associated
with levels of sCD14 in SLE. We found a significant negative
correlation between the ratio of EndoCAb IgM:total IgM and
sCD14 (P = 0.030; r = −0.396) (Figure 4). Since bacterial
exposure reduces EndoCAb IgM and elevates sCD14, this
relationship is not surprising.
Lysozyme Levels Are Increased in
SLE Patients
Peptidoglycan comprises a high proportion of the cell walls
of Gram-positive and Gram-negative bacteria (32). Lysozyme
is an important antimicrobial enzyme that hydrolyses the
glycocidic bond of the peptidoglycan to kill microorganisms (33).
Lysozyme is produced by monocytes, macrophages, neutrophils,
and glandular cells (33). Levels of lysozyme are elevated in many
diseases characterized by gut hyperpermeability including celiac
disease, colitis, and Crohn’s disease, suggesting that microbial
flora upregulates this enzyme (33, 34). We tested lysozyme levels
and found a significant increase in SLE patients (P < 0.0001)
compared to controls. Both SLE males (P < 0.0001) and females
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FIGURE 1 | Increased levels of sCD14 in SLE subjects. (A) Concentrations of circulating sCD14 in healthy controls and SLE patients. (B) Concentrations of LBP in
healthy controls and SLE patients. Bars represent median analyte levels. (C) Correlation between circulating sCD14 levels and the SELENA-SLEDAI score in SLE
patients. Correlation studies showed a significant positive correlation between SLEDAI vs. sCD14 (n = 20).
(P = 0.021) exhibited a significant elevation when compared to
controls (Figure 5A).
Concentrations of FABP2 Are Not Different
in SLE Patients
Changes in the levels of FABP2 in the circulation reflects
epithelial cell loss and alterations in enterocyte turnover rate
in the intestine. Thus, FABP2 serves as a useful marker
in assessing intestinal permeability (20). We found that the
levels of FABP2 were not different in these SLE subjects
(P = 0.285 healthy controls vs. SLE patients; P = 0.201 control
males vs. SLE males; and P = 0.698 control females vs. SLE
females) (Figure 5B).
Lysozyme Levels Positively Correlate With
sCD14, LBP, and FABP2 Levels
We observed a significant positive correlation between the
antibacterial protein lysozymewith sCD14 (r= 0.499, P= 0.005),
LBP (r = 0.434, P = 0.016), and FABP2 (r = 0.396, P = 0.030) in
SLE patients as determined by Pearson’s r analysis. We did not
observe any correlation between these factors in healthy controls
(Figures 6A–C). Even though there is no statistical difference in
LBP and FABP2 levels in SLE, their correlation with lysozyme
suggests a common stimulus.
Galectin-3 Levels in Healthy Controls and
SLE Cohorts
Galectin-3 is a multifunctional β-galactoside-binding protein
produced by macrophages, monocytes, and dendritic cells (35).
Previous reports demonstrated its upregulation in autoimmune
disorders such as rheumatoid arthritis, Behcet’s disease, and SLE
(36–38). Exposure to bacterial products is suggested to induce
the secretion of galectin-3 and the interaction between galectin-3
and LPS potentiates inflammation (39–41). Moreover, galectin-
3 is involved in the regulation of immune and inflammatory
responses (42). In our study, we found that galectin-3 levels were
not statistically significant (P = 0.172 healthy controls vs. total
SLE; male SLE subjects (P = 0.213); female SLE subjects (P =
0.532) (Figure 7A).
Galectin-3 Levels Positively Correlate With
sCD14 and Lysozyme in SLE Subjects
A significant positive correlation was seen for galectin-3 levels
with sCD14 (r = 0.425, P = 0.019), lysozyme (r = 0.447, P =
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FIGURE 2 | EndoCAb IgM levels are reduced in SLE subjects. (A) Levels of circulating EndoCAb IgG in healthy controls and SLE patients. (B) Circulating EndoCAb
IgA levels in healthy controls and SLE subjects. (C) Levels of circulating EndoCAb IgM in healthy controls and SLE patients. (D) Levels of circulating total IgG in healthy
controls and SLE patients. (E) Levels of circulating total IgA in healthy controls and SLE patients. (F) Levels of circulating total IgM in healthy controls and SLE
patients. (G) Ratio of EndoCAb IgG:total IgG in healthy controls and SLE patients. (H) Ratio of EndoCAb IgA:total IgA in healthy controls and SLE patients. (I) Ratio of
EndoCAb IgM:total IgM is reduced among SLE patients compared to healthy controls. For all figures, bars represent median analyte levels.
0.013), and LBP in SLE patients (r = 0.416, P = 0.022). We
did not observe such a positive correlation in healthy controls
for lysozyme and sCD14. However, galectin-3 vs. LBP (r =
0.524, P = 0.002) was positively correlated in normal subjects.
Interestingly, a negative correlation was observed between
galectin-3 and sCD14 in healthy controls, but the correlation
did not achieve statistical significance (r = −0.163, P = 0.387)
(Figures 7B–D).
Concentrations of LL-37 in SLE Cohort
Were Not Different Than Those in Healthy
Controls
LL-37 is an antimicrobial peptide produced in response to
bacteria and their products (43, 44). LL-37 can act as either a
pro- or anti-inflammatory peptide depending on the context in
which it is involved (45). We did not find any significant change
in the concentration of LL-37 in SLE patients when compared
to healthy controls (P = 0.449), SLE males compared to control
males (P = 0.504), and SLE females compared to control females
(P = 0.733) (Figure 8A).
Levels of CXCL16 Are Increased in SLE
Patients and Positively Correlated With
sCD14 Levels
CXCL16 is an important multifunctional antimicrobial protein
secreted by macrophages and dendritic cells and is involved in
the phagocytosis of bacteria (46, 47). We observed a significant
increase in the levels of CXCL16 (p = 0.001) in SLE patients
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FIGURE 3 | Ratios of EndoCAbs:total immunoglobulins are not affected by disease modulating drugs. (A–C) Concentrations of total immunoglobulins in SLE subjects
(n = 19) treated with immunosuppressive and/or immunomodulatory drugs such as hydroxychloroquine, mycophenolate mofetil and/or azathioprine (n = 19)
compared with untreated SLE subjects (n = 11). (D–F) Concentrations of EndoCAbs in untreated SLE patients (n = 11) and those treated with immunosuppressive
drugs (n = 19). (G–I) Ratios of EndoCAbs:total Igs in SLE patients in untreated SLE subjects (n = 11) and those treated with immunosuppressive and/or
immunomodulatory drugs (n = 19). Bars represent median analyte levels for all figures.
when compared to control subjects (Figure 8B). SLE males were
significantly different from control males (P = 0.002) whereas
SLE females only showed a trend toward significance (P= 0.081).
A significant positive correlation was observed between
CXCL16 levels and sCD14 levels in both SLE patients (r =
0.551, P = 0.001) and healthy controls (r = 0.411, P = 0.023)
(Figure 8C). This could be due to the involvement of a common
stimulus driving the elevation of both CXCL16 and sCD14 levels.
DISCUSSION
In this investigation, we demonstrated coordinated changes
in ARFs in SLE patients. Constituents from Gram-negative
and Gram-positive bacteria including LPS, peptidoglycan,
flagellin, endogenous lipids, and lipoteichoic acid (LTA) can
stimulate monocyte/macrophage activation and induce ARFs
(48, 49). ARFs are predominantly expressed and produced
by monocytes/macrophages, neutrophils, hepatocytes, and
B cells (23, 49–53) which initiate a cascade of protective
immunoregulatory and proinflammatory factors potentiating
bacterial clearance. This mechanism could initiate or
accelerate SLE.
We found that sCD14 levels were increased in SLE, confirming
previous studies (23, 54, 55). Recent reports demonstrated that
elevated levels of sCD14 in plasma are associated with intestinal
barrier dysfunction (56, 57). The positive correlation between
sCD14 and disease activity (SELENA-SLEDAI score) levels
suggests a role for endotoxemia in SLE progression. LPS exposure
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FIGURE 4 | sCD14 levels correlate with the ratio of EndoCAb IgM:total IgM in
SLE patients. Analysis showing a significant negative correlation between
sCD14 and the ratio of EndoCAb IgM:Total IgM in SLE patients.
could thus account for many of the findings in this study.
sCD14 levels are increased in other bacterial infection-associated
diseases including sepsis, arthritis, periodontitis, and kidney
diseases. Elevated levels of sCD14 in the circulation indicates
a systemic response to bacterial exposure (58–61). Correlation
of sCD14 with SELENA-SLEDAI in SLE indicates that sCD14
could be an acute phase protein. Furthermore, it is known that
excess sCD14 levels reduce the LPS-monocyte interaction and
thereby decrease the detrimental effects of systemic leukocyte
activation (60, 62). Increased levels of sCD14 in the circulation
promote the release of LPS from cells. Due to the rapid binding
of LPS with monocytes/macrophages, released LPS can further
stimulate the production of proinflammatory cytokines. LPS
is also transferred to lipoproteins for its neutralization (60).
Interestingly, endogenous lipoproteins cannot neutralize LPS
quickly due to their slow binding rate (63). The biological effects
of sCD14 appear to be concentration dependent and further
investigations are required to understand the effects of sCD14
mediated release of cell bound LPS.
We did not observe any significant changes in the levels
of LBP, a marker in the LPS-CD14 pathway, in SLE cohort
compared to healthy controls. The absence of a significant
change in LPS-binding molecules could be due to differences
in affinity, production, or clearance, or perhaps by the low
molar ratio of LPS to these relatively abundant ligands (64). At
the same time, increased levels of sCD14 levels could also be
due to monocyte/macrophage activation by elevated levels of
inflammatory cytokines (49). Since the elevated levels of sCD14
do not reflect the sole involvement of bacterial products, further
studies are warranted to define the exact basis of elevated levels
of sCD14 in lupus.
The reduction in the ratio of EndoCAb IgM:IgM levels
is particularly provocative, since this immunoglobulin directly
neutralizes LPS. To our knowledge, this is the first report
analyzing EndoCAb levels in SLE. EndoCAb IgM antibody levels
are reduced during an antimicrobial response and act as a
sensitive marker of recent endotoxin exposure (20, 28, 64). It
was hypothesized that binding and neutralization of endotoxin
by EndoCAb IgM leads to its subsequent degradation, reflecting
its reduced levels (65). Thus, EndoCAb IgM antibody titres
are inversely proportional to acute endotoxemia (66, 67). We
observed reduced levels of EndoCAb IgM and elevated levels
of sCD14 in the SLE cohort. Moreover, a negative correlation
between sCD14 and the ratio of EndoCAb IgM:Total IgM also
links the EndoCAb mediated clearance of LPS. Since elevated
levels of sCD14 in plasma enhance LPS release from monocytes,
it is quite likely that the reduction of EndoCAb IgM is due to the
binding of free endotoxins. Alternatively, sustained depletion of
EndoCAb IgG is found during chronic endotoxemia including
sepsis (28). Currently, it is unknown about the initiating events
and the exact fate of endotoxin-EndoCAb complex and/or
whether this complex has any specific role in the activation of the
complement pathway. Follow-up studies are pertinent to address
this question.
The significant increase in the levels of total IgA and IgG
observed in this SLE cohort could be due to immune activation.
Previous studies also reported elevated levels of IgA and IgG
in lupus patients (30, 31). It was shown that higher amounts
of immunoglobulin secreting cells in the peripheral blood are
responsible for the elevated levels of IgA and IgG in SLE (68).
Moreover, IgG plays an important role in the formation of
immune complexes in SLE, which induce a chronic inflammatory
condition (69, 70). Elevated levels of IgA could result as an
immune response from the mucosal immune system against
translocated bacterial products (71). Even though the ratios of
EndoCAb IgA:total IgA and EndoCAb IgG:total IgG were not
significantly different among the groups, the ratio of EndoCAb
IgA:total IgA in SLE females showed a trend toward significant
reduction suggesting exposure of bacterial products from the gut.
Immunosuppression may lead to increased bacterial growth
and infection (72, 73). Increased exposure to microbial products
could be due to gut leakiness and/or infection that could
result from immunosuppression. It was previously reported
that immunosuppression can somewhat reduce the levels of
EndoCAbs but the results were not statistically significant (74).
In this report, we showed that EndoCAb IgM levels were
lower in SLE subjects treated with immunosuppressive and/or
immunomodulatory drugs that included hydroxychloroquin,
mycophenolate mofetil, and azathioprine. However, the ratio
of EndoCAb IgM:Total IgM was significantly reduced in SLE
subjects. This suggests a specific effect on EndoCAb IgM
indicating increased LPS exposure. The negative correlation
between sCD14 and the ratio of EndoCAb IgM:total IgM suggests
bacterial exposure and monocyte/macrophage activation.
We found elevated levels of lysozyme in SLE patients. Previous
studies reported an elevation of this enzyme in response to
microbial exposure and alterations in intestinal permeability
(33, 34, 75). Bacterial exposure increases monocyte/macrophage
and neutrophil activation (76, 77). Activated macrophage
produce proinflammatory cytokines such as IL-6 and TNF-α
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FIGURE 5 | Elevated levels of lysozyme in SLE subjects. (A) Levels of circulating lysozyme in healthy controls and SLE patients. (B) FABP2 levels remain unchanged
in healthy controls and SLE patients. Bars represent median analyte levels for all figures.
FIGURE 6 | Circulating levels of lysozyme correlate with sCD14, LBP, and FABP2 in SLE patients. (A–C) Analysis showing a significant positive correlation of lysozyme
with sCD14, LBP, and FABP2 in SLE patients.
can increase the production of lysozyme (33, 78). Although
we did not find significant differences in LBP or FABP2
levels, we observed significant positive correlations between
lysozyme levels and sCD14, LBP and FABP2. This suggests
a relationship and possible common stimulus for these
factors. Interestingly, the positive correlations between these
factors appear to be novel and have never been reported
in SLE.
Our analyses also indicated that the SLE cohort possesses
increased levels of CXCL16 compared to healthy controls.
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FIGURE 7 | Galectin-3 levels correlate with sCD14, lysozyme and LBP in SLE subjects. (A) Plasma galectin-3 levels were not significantly different in SLE patients
compared to healthy controls. Bars represent median analyte levels. (B–D) Correlation of galectin-3 levels with sCD14, lysozyme, and LBP in healthy controls and SLE
patients. A significant positive correlation with sCD14, lysozyme, and LBP was observed in SLE patients. In healthy controls, a positive correlation was observed with
galectin-3 vs. LBP (D) and a non-significant negative correlation was observed with galectin-3 vs. sCD14 (B).
CXCL16 is an important chemokine participating in host defense
and acts as a mediator of innate immune responses (79).
Recent studies showed the involvement of CXCL16 in SLE
patients (51, 80). In addition to macrophages and dendritic cells,
CXCL16 is also produced by keratinocytes, where it plays an
antimicrobial role (79). Qin et al. (51) reported higher levels of
CXCL16 in SLE patients with cutaneous disease compared to
subjects without cutaneous involvement. We did not observe
any correlation between CXCL16 levels and disease activity in
male and female SLE patients (data not shown). Endotoxemia
also increases the levels of CXCL16 (81). Increased levels of
CXCL16 in SLE cohort might be due to the exposure of bacterial
products. CXCL16 is recognized as a novel class of scavenger
receptor. The role of scavenger receptors in the uptake of
modified LDL is well-reported (82). Moreover, involvement of
CXCL16 in the phagocytosis of both Gram-negative and Gram-
positive bacteria was also documented (46). A positive correlation
between CXCL16 and sCD14 in our study further substantiate
the involvement of bacterial products for the elevation of
CXCL16 in SLE patients. Binding of LPS with CD14 leads to
the activation of various signaling cascades including NF-κB
and drives the induction of CXCL16 (81). It is reported that
LPS binds to lipoproteins and the resulting LPS-lipoprotein
complex undergoes receptor-mediated endocytosis (63, 83). As
a scavenger receptor, elevated levels of CXCL16 appears to
be a compensatory mechanism to neutralize LPS-lipoprotein
complexes. Considering these observations, it is likely that the
increased level of CXCL16 in SLE cohorts results from bacterial
exposure. Follow-up studies will be necessary to clarify the
functional role of CXCL16 in the transport of bacterial products
and its receptor-mediated neutralization.
Galectin-3 acts as a regulator of innate immunity or as a
pattern-recognition receptor (84, 85). Plasma galectin-3 levels
have been reported to be significantly elevated in SLE (38).
However, our analysis of galectin-3 levels did not reveal
significant alterations. The differences in results between these
studies could reflect the male to female ratio or disease severity.
Shi et al. (38) used a predominantly female cohort with a SLEDAI
score average of 12.5 as compared to our cohort, which included
43% males, and subjects with an average SLEDAI score of 4.9.
Yet following gender stratification of our SLE subjects, the female
cohort showed no signs of increase in galectin-3 levels. Moreover,
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FIGURE 8 | Concentrations of CXCL16 are elevated in SLE subjects. (A) Concentration of LL-37 remains unchanged in SLE patients compared with healthy controls
and SLE patients. (B) SLE patients have elevated levels of CXCL16 levels compared to healthy controls. (C) CXCL16 levels were positively correlated with sCD14
levels in both SLE patients and healthy controls.
we did not observe a correlation between disease activity and
galectin-3 levels (data not shown). Therefore, further studies
are required to elucidate the role galectin-3 in the pathology of
SLE. Interestingly, a positive correlation between galectin-3 with
sCD14, lysozyme, and LBP in our study suggests the involvement
of bacterial exposure as a common stimulus.
SLE primarily affects women. There has been a lot of progress
in delineating the pathophysiology of the disease, but the female
predominance is still unexplained (1). Interestingly, we observed
some gender differences in ARF levels. For example, EndoCAb
IgM levels were reduced in females, whereas males only showed
a trend. Conversely, CXCL16 levels were increased in male SLE
subjects, whereas females showed a trend. Males and females
show different levels of innate immunity and the alterations
in innate immunity lead to the production of auto-antigens
and autoimmunity in SLE (86–88). Various studies indicated
the involvement of immune responses from intestinal mucosa
in determining gender differences in SLE (89). Differences
in gut microbiome between males and females could be a
possible reason for gender-specific changes in the levels of ARFs
in this study. Gender-specific differences in gut microbiome
composition have been widely reported (90–92). Furthermore,
microbiota composition differs between males and females in
other autoimmune conditions, which further demonstrate a
possible connection between gender, the gut microbiome and
immunity (90, 93–95). It is suggested that sex-specific changes in
the composition of gut microbiota may be a contributing factor
for more severe lupus symptoms in females (90).
We believe that the unifying stimulus for the observed
differences in ARF levels in SLE subjects is bacterial exposure.
Several factors, such as increased intestinal permeability,
alterations in gut flora, and changes in the morphology of
the intestine could contribute to the heightened antimicrobial
response observed in our study. In human SLE, a relative
increase in the abundance of Lachnospiraceae and a lower ratio
of Firmicutes to Bacteroidetes was demonstrated (14–16, 96).
Alterations inmicrobiota may inhibit intestinal barrier functions,
triggering inflammation and antimicrobial defense mechanisms
(97). It was shown that the receptors for LPS and peptidoglycans
(TLR4 and TLR2, respectively) are elevated in SLE, which
promote pathology and autoantibody production (13, 98, 99).
Although we observed no significant change in the levels of
FABP2 (marker of compromised intestinal integrity), we did find
a positive correlation between FABP2 and lysozyme, suggesting
the involvement of bacterial exposure in SLE cohort. Due to
broad variance in the levels of FABP2, the difference may be hard
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FIGURE 9 | Schematic representation of heightened antimicrobial response in SLE. Release of LPS and other microbial products into systemic circulation causes
monocyte/macrophage activation and the release of antimicrobial response factors (ARFs). Elevated levels of sCD14 are an indication of monocyte/macrophage
activation. High sCD14 can also accelerate the release of cell bound LPS from monocytes. Binding and neutralization of free endotoxins by EndoCAb IgM causes its
reduction in the circulation. In addition, other ARFs such as lysozyme and CXCL16 are induced to combat and neutralize the bacterial products in the circulation. A
positive correlation of sCD14 with lysozyme and CXCL16 and a negative correlation between sCD14 and the ratio of EndoCAb IgM:Total IgM suggests that exposure
to microbial products is a common stimulus for the induction of these ARFs. Compromised intestinal integrity is the likely reason for the translocation of microbial
products into the circulation. In order to query and define this, case-control studies in SLE analyzing the suite of different markers of intestinal permeability are essential.
to detect with this sample size. In the absence of a significant
change in FABP2 levels, measuring circulating LPS, zonulin,
and intestinal biopsy are alternatives for assessing compromised
gut integrity. However, none of these approaches is without
pitfalls. For example, circulating LPS and zonulin levels are not
considered reliable markers for compromised gut permeability
due to technical difficulties in quantification (57, 100–103). The
acquisition of intestinal tissue from SLE patients and controls
is uncommon, which makes such an approach less feasible.
For these and other reasons, assessment of biomarkers related
to microbial exposure and immune activation is considered
one of the best possible measures of analyzing compromised
gut permeability in humans using archived serum or plasma
samples (57, 104).
In conclusion, our results demonstrate a heightened
antimicrobial response with marked elevations and
correlations of ARFs in SLE (Figure 9). Based on our
results, it appears that inhibiting microbial exposure
may dampen monocyte/macrophage activation and
improve therapeutic outcomes for SLE patients. Indeed,
pre-clinical studies showed that antibiotic treatment
ameliorated systemic autoimmunity, increased intestinal
epithelial barrier function and eliminated pathogenic
autoantibodies and T cells in SLE (7, 8). However, a better
understanding of the linkage between SLE and heightened
antimicrobial responses could provide novel therapeutic
approaches for the management of this disease in high
risk populations.
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